Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Time-course Analysis of Bone Loss Induced by Bilateral Ovariectomy in BDF-1 Hybrid Mice

  • Dahyeon Yoo (Department of Biomedical Laboratory Science, Eulji University) ;
  • Jaewang Lee (Department of Senior Healthcare, Graduate School of Eulji University)
  • Received : 2024.10.16
  • Accepted : 2024.12.09
  • Published : 2024.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Osteoporosis is a major health concern in postmenopausal women. The aim of this study was to investigate the time-course bone loss phenomenon caused by bilateral ovariectomy (biOVX) through bioimaging, biochemical, and histological analyses. Methods: In this study, 8-week-old BDF-1 hybrid female mice were subjected to biOVX to induce bone loss. Following biOVX, the mice were randomly assigned to five groups (sham control without biOVX, and groups sacrificed at 4, 8, and 12 weeks post-biOVX). The mice were sacrificed to collect dual-energy X-ray absorptiometry images, blood serum, and bone samples for further analysis at 4, 8, and 12 weeks post-biOVX. Results: Four weeks after biOVX, all osteoporosis-related biomarkers (serum Ca2+, Mg2+, bone mineral content, bone mineral density [BMD], and bone volume [BV] in the femur) were significantly decreased compared with sham controls. Bilateral OVX continued to show reduced serum Ca2+, BMD, and BV at 8 weeks post-surgery. Histomorphological changes in the femoral bone were also observed at 4 weeks and persisted until 12 weeks post-biOVX. Conclusion: This study confirmed the time-course bone loss caused by biOVX through X-ray imaging, biochemical, and histological analyses. Based on these findings, we suggest that biOVX is a robust model for studying osteoporosis. However, further studies are still required.

Keywords

Acknowledgement

This project was financially supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2018R1D-1A1B07046419).

References

  1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-33. https://doi.org/10.1007/s00198-006-0172-4
  2. Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008;42:4-15. https://doi.org/10.1016/j.bone.2007.10.019
  3. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033-46. https://doi.org/10.1007/s00198-007-0343-y
  4. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2007;11:iii-iv, ix-xi, 1-231.
  5. Park SB, Lee YJ, Chung CK. Bone mineral density changes after ovariectomy in rats as an osteopenic model: stepwise description of double dorso-lateral approach. J Korean Neurosurg Soc. 2010;48:309-12. https://doi.org/10.3340/jkns.2010.48.4.309
  6. Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA. The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008;58:424-30.
  7. Komori T. Animal models for osteoporosis. Eur J Pharmacol. 2015;759:287-94. https://doi.org/10.1016/j.ejphar.2015.03.028
  8. Chavassieux P, Garnero P, Duboeuf F, Vergnaud P, Brunner Ferber F, Delmas PD, et al. Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study. J Bone Miner Res. 2001;16:89-96. https://doi.org/10.1359/jbmr.2001.16.1.89
  9. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88-91. https://doi.org/10.1126/science.1621100
  10. Li H, Miyahara T, Tezuka Y, Namba T, Nemoto N, Tonami S, et al. The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan. Biol Pharm Bull. 1998;21:1322-6. https://doi.org/10.1248/bpb.21.1322
  11. Ma Q, Liang M, Wang Y, Ding N, Wu Y, Duan L, et al. Noncoenzyme role of vitamin B1 in RANKL-induced osteoclastogenesis and ovariectomy induced osteoporosis. J Cell Biochem. 2020;121:3526-36. https://doi.org/10.1002/jcb.29632
  12. Wronski TJ, Cintrón M, Dann LM. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int. 1988;43:179-83. https://doi.org/10.1007/BF02571317
  13. Wronski TJ, Cintrón M, Doherty AL, Dann LM. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology. 1988;123:681-6. https://doi.org/10.1210/endo-123-2-681
  14. Yamaguchi T, Hattori S, Nakai M, Sekita K, Fujita Y. A study on the biological significance of midregion and intact parathyroid hormone in hemodialysis patients. Endocr J. 1997;44:289-97. https://doi.org/10.1507/endocrj.44.289
  15. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone. 1996;18:621-7. https://doi.org/10.1016/8756-3282(96)00085-3
  16. Lee J, Kim SK, Youm HW, Kim HJ, Lee JR, Suh CS, et al. Effects of three different types of antifreeze proteins on mouse ovarian tissue cryopreservation and transplantation. PLoS One. 2015;10:e0126252. https://doi.org/10.1371/journal.pone.0126252
  17. Shin J, Woo J, Cho Y, Choi YH, Shin NN, Kim Y. Four-week individual caging of male ICR mice alters body composition without change in body mass. Sci Rep. 2018;8:1331. https://doi.org/10.1038/s41598-018-19808-x
  18. Lee J, Kim EJ, Kong HS, Youm HW, Lee JR, Suh CS, et al. A combination of simvastatin and methylprednisolone improves the quality of vitrified-warmed ovarian tissue after auto-transplantation. Hum Reprod. 2015;30:2627-38. https://doi.org/10.1093/humrep/dev222
  19. Lee J, Kong HS, Kim EJ, Youm HW, Lee JR, Suh CS, et al. Ovarian injury during cryopreservation and transplantation in mice: a comparative study between cryoinjury and ischemic injury. Hum Reprod. 2016;31:1827-37. https://doi.org/10.1093/humrep/dew144
  20. Bauss F, Dempster DW. Effects of ibandronate on bone quality: preclinical studies. Bone. 2007;40:265-73. https://doi.org/10.1016/j.bone.2006.08.002
  21. Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 1991;15:175-91. https://doi.org/10.1016/0169-6009(91)90124-I
  22. Miller SC, Bowman BM, Jee WS. Available animal models of osteopenia--small and large. Bone. 1995;17:S117-23. https://doi.org/10.1016/8756-3282(95)00284-K
  23. Suzuki M, Millecamps M, Naso L, Ohtori S, Mori C, Stone LS. Chronic osteoporotic pain in mice: cutaneous and deep musculoskeletal pain are partially independent of bone resorption and differentially sensitive to pharmacological interventions. J Osteoporos. 2017;2017:7582716. https://doi.org/10.1155/2017/7582716
  24. Song L, Bi YN, Zhang PY, Yuan XM, Liu Y, Zhang Y, et al. Optimization of the time window of interest in ovariectomized imprinting control region mice for antiosteoporosis research. Biomed Res Int. 2017;2017:8417814. https://doi.org/10.1155/2017/8417814
  25. Abu-Taha M, Rius C, Hermenegildo C, Noguera I, Cerda Nicolas JM, Issekutz AC, et al. Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol. 2009;183:1393-402. https://doi.org/10.4049/jimmunol.0803157
  26. Kitajima Y, Doi H, Ono Y, Urata Y, Goto S, Kitajima M, et al. Estrogen deficiency heterogeneously affects tissue specific stem cells in mice. Sci Rep. 2015;5:12861. https://doi.org/10.1038/srep12861
  27. Lizcano F, Guzmán G. Estrogen deficiency and the origin of obesity during menopause. Biomed Res Int. 2014;2014:757461. https://doi.org/10.1155/2014/757461
  28. Walf AA, Rhodes ME, Meade JR, Harney JP, Frye CA. Estradiol-induced conditioned place preference may require actions at estrogen receptors in the nucleus accumbens. Neuropsychopharmacology. 2007;32:522-30. https://doi.org/10.1038/sj.npp.1301124
  29. Quinn MA, Xu X, Ronfani M, Cidlowski JA. Estrogen deficiency promotes hepatic steatosis via a glucocorticoid receptor-dependent mechanism in mice. Cell Rep. 2018;22:2690-701. https://doi.org/10.1016/j.celrep.2018.02.041
  30. Yoshida T, Takahashi K, Yamatani H, Takata K, Kurachi H. Impact of surgical menopause on lipid and bone metabolism. Climacteric. 2011;14:445-52. https://doi.org/10.3109/13697137.2011.562994
  31. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis: its clinical features. JAMA. 1941;116:2465-74. https://doi.org/10.1001/jama.1941.02820220007002
  32. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988;241:84-6. https://doi.org/10.1126/science.3388021
  33. Riggs BL, Jowsey J, Kelly PJ, Jones JD, Maher FT. Effect of sex hormones on bone in primary osteoporosis. J Clin Invest. 1969;48:1065-72. https://doi.org/10.1172/JCI106062
  34. Vedi S, Compston JE. The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women. Bone. 1996;19:535-9. https://doi.org/10.1016/S8756-3282(96)00227-X
  35. Li L, Wang Z. Ovarian aging and osteoporosis. Adv Exp Med Biol. 2018;1086:199-215. https://doi.org/10.1007/978-981-13-1117-8_13
  36. Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev. 2020;1:CD012559. https://doi.org/10.1002/14651858.CD012559.pub2
  37. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92:982-8. https://doi.org/10.1097/00006250-199812000-00019
  38. Humphries KH, Gill S. Risks and benefits of hormone replacement therapy: the evidence speaks. CMAJ. 2003;168:1001-10.
  39. Studd J. Complications of hormone replacement therapy in post-menopausal women. J R Soc Med. 1992;85:376-8.
  40. Sittadjody S, Enck KM, Wells A, Yoo JJ, Atala A, Saul JM, et al. Encapsulation of mesenchymal stem cells in 3D ovarian cell constructs promotes stable and long-term hormone secretion with improved physiological outcomes in a syngeneic rat model. Ann Biomed Eng. 2020;48:1058-70. https://doi.org/10.1007/s10439-019-02334-w
  41. Sittadjody S, Saul JM, McQuilling JP, Joo S, Register TC, Yoo JJ, et al. In vivo transplantation of 3D encapsulated ovarian constructs in rats corrects abnormalities of ovarian failure. Nat Commun. 2017;8:1858. https://doi.org/10.1038/s41467-017-01851-3